Lower-Dose Dexamethasone May Prevent Paclitaxel HSRs
Key Takeaways
- Among patients receiving weekly paclitaxel, lower-dose dexamethasone was reported as non-inferior to conventional dosing for hypersensitivity reactions during the second infusion.
- The compared regimens were dexamethasone 10 mg at the first infusion followed by 4 mg weekly versus 10 mg weekly, and the primary analysis used a predefined 2% non-inferiority margin.
- In adjusted safety analyses, hyperglycemia risk was higher in the high-dose group, while insomnia and serious bacterial infections were numerically more frequent but did not reach statistical significance.
The report described a retrospective cohort study using electronic health records in patients receiving weekly paclitaxel. Investigators compared a low-dose dexamethasone regimen of 10 mg at the first infusion followed by 4 mg weekly with a conventional high-dose regimen of 10 mg weekly, using hypersensitivity reactions during the second paclitaxel infusion as the primary outcome within a predefined 2% non-inferiority margin. To address measured confounding and missingness, the analysis used propensity score-based inverse probability of treatment weighting and multiple imputation, and the authors reported the lower-dose regimen as non-inferior in that second-infusion comparison.
For steroid-related adverse events, the adjusted adverse-event analysis showed a higher risk of hyperglycemia in the high-dose group, with an adjusted hazard ratio of 1.54 (95% CI 1.15 to 2.07). Insomnia also occurred more frequently numerically with high-dose dexamethasone, with an adjusted hazard ratio of 1.53 (95% CI 0.93 to 2.51), and serious bacterial infections were likewise numerically higher at 1.19 (95% CI 0.99 to 1.44), but neither comparison was reported as statistically significant.
Clinician Questions
What dexamethasone regimens were compared before weekly paclitaxel in the retrospective cohort?
The retrospective cohort compared low-dose dexamethasone 10 mg at the first paclitaxel infusion followed by 4 mg weekly with conventional high-dose dexamethasone 10 mg weekly in patients receiving weekly paclitaxel.
What were the reported second-infusion hypersensitivity rates with low-dose vs high-dose dexamethasone before weekly paclitaxel?
Before weekly paclitaxel, low-dose dexamethasone had a weighted second-infusion hypersensitivity incidence of 0.72% and high-dose dexamethasone had a weighted incidence of 1.18%, corresponding to a risk difference of -0.46% (95% CI -1.26% to 0.53%) within the predefined non-inferiority framework for hypersensitivity reactions during the second paclitaxel infusion.
How did hyperglycemia, insomnia, and serious bacterial infections compare between dexamethasone doses during weekly paclitaxel?
During weekly paclitaxel, the high-dose dexamethasone group had a higher adjusted hazard of hyperglycemia, with an adjusted hazard ratio of 1.54 (95% CI 1.15 to 2.07), while insomnia (adjusted hazard ratio 1.53, 95% CI 0.93 to 2.51) and serious bacterial infections (adjusted hazard ratio 1.19, 95% CI 0.99 to 1.44) were numerically more frequent but were not statistically significant according to the source.